Jaipur: The life of 20-month-old Kartik hangs in balance. Diagnosed with spinal muscular atrophy (SMA), a rare and life-threatening neuromuscular dise.

Improving sleep quality with SMA can involve support for physical comfort, breathing, muscle weakness, and body temperature.

Speech therapy helps people with SMA by improving speech clarity, breath control, swallowing, and communication device use.

Emerging Spinal Muscular Atrophy therapies in the different phases of clinical trials are- SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept ...

European Commission approves Roche’s Evrysdi tablet to treat spinal muscular atrophy: Basel Thursday, June 5, 2025, 09:00 Hrs [IST] Roche announced that the European Commission ...

Taiwanese company AnnJi Pharmaceutical has reported encouraging outcomes from its randomised, placebo-controlled Phase I/IIa trial of AJ201, an investigational compound for treating the adult ...

Salem Y. Physical therapy guide to spinal muscular atrophy. ChoosePT. Updated August 3, 2021. Accessed February 2, 2025. Diagnosis: spinal muscular atrophy (SMA). Muscular Dystrophy Association (MDA).

Results from the STEER and STRENGTH studies showed that OAV101 IT led to a 2.39-point improvement in motor function in patients with spinal muscular atrophy. Results from the Phase III STEER and Phase ...

Video: Balancing the Benefits and Burdens of Therapy in Patients with Pediatric Spinal Muscular Atrophy —Ashley E. Webb, MD, neuromuscular program director at UTHealth, Houston, describes the ...

Novartis finally delivers gene therapy data in older SMA patients. Will they still want it? Since Zolgensma’s approval for babies with spinal muscular atrophy, other treatments have hit the market ...

Spinal bulbar muscular atrophy (SBMA) is a progressive genetic neuromuscular condition that affects motor neurons. Over time, it may cause symptoms such as difficulty speaking, swallowing, or walking.

Prenatal therapy for spinal muscular atrophy (SMA) with risdiplam has shown promise in a first-of-its-kind study led by Richard Finkel, MD, St. Jude Center for Experimental Neurotherapeutics ...